Chapter 12. Antiplatelet Therapy in Chronic Coronary Artery Disease

  1. Stephen D. Wiviott MD Assistant Professor Investigator
  1. Kamran I. Muhammad MD Fellow in Cardiovascular Medicine1 and
  2. Deepak L. Bhatt MD, FACC, FAHA Chief of Cardiology Director Senior Investigator2

Published Online: 19 FEB 2009

DOI: 10.1002/9781444303339.ch12

Antiplatelet Therapy In Ischemic Heart Disease

Antiplatelet Therapy In Ischemic Heart Disease

How to Cite

Muhammad, K. I. and Bhatt, D. L. (2008) Antiplatelet Therapy in Chronic Coronary Artery Disease, in Antiplatelet Therapy In Ischemic Heart Disease (ed S. D. Wiviott), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303339.ch12

Editor Information

  1. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, TIMI Study Group, Boston, MA, USA

Author Information

  1. 1

    Cleveland Clinic Cleveland, OH, USA

  2. 2

    VA Boston Healthcare System, Integrated Interventional Cardiovascular Program at Brigham and Women's Hospital and the VA Boston Healthcare System, TIMI Study Group Boston, MA USA

Publication History

  1. Published Online: 19 FEB 2009
  2. Published Print: 28 NOV 2008

Book Series:

  1. The AHA Clinical Series

Book Series Editors:

  1. Elliott Antman MD, FAHA

Series Editor Information

  1. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, TIMI Study Group, Boston, MA, USA

ISBN Information

Print ISBN: 9781405176262

Online ISBN: 9781444303339

SEARCH

Keywords:

  • chronic coronary artery disease (CAD);
  • Antithrombotic Trialists’ Collaboration (ATC);
  • Swedish angina pectoris aspirin trial (SAPAT);
  • aspirin in chronic coronary artery disease without previous MI;
  • aspirin resistance;
  • Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study;
  • oral ADP receptor antagonists, prasugrel and AZD6140 - Novel agents;
  • dual antiplatelet therapy - clopidogrel plus aspirin

Summary

This chapter contains sections titled:

  • Aspirin

  • ADP receptor antagonists

  • Dual antiplatelet therapy: clopidogrel plus aspirin

  • Oral glycoprotein IIb/IIIa inhibitors

  • Other antiplatelet agents

  • Antiplatelet therapy after percutaneous coronary intervention in chronic coronary artery disease

  • Conclusion

  • References